Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...

Medipost transitioned from cord blood banking to developing stem cell therapies, focusing on knee osteoarthritis and other ...

Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for ...

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, ...

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, ...

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...

Aside from the MFN order, President Trump is also in the process of negotiating tariffs with countries all over the world. It ...

FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...